Loading...
•
Jun 30, 2023
Replimune Q1 2024 Earnings Report
Reported financial results for the fiscal first quarter ended June 30, 2023 and provided a business update.
Key Takeaways
Replimune reported its fiscal first quarter 2024 financial results, highlighting positive updates for RP1 in anti-PD1 failed melanoma and RP2 in uveal melanoma presented at ASCO. Top-line data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo in cutaneous squamous cell carcinoma is expected in early Q4 2023, and a BLA submission is anticipated in Q1/2 2024. A cost-sharing collaboration in cutaneous squamous cell carcinoma in the neoadjuvant setting was entered into with Incyte.
Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo in cutaneous squamous cell carcinoma expected in early Q4 2023 and Biologics License Application submission anticipated in Q1/2 2024.
Cost sharing collaboration in cutaneous squamous cell carcinoma in the neoadjuvant setting entered into with Incyte.
Data snapshot for all 141 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma expected Q4 2023.
Strong balance sheet with cash runway into H2 2025.
Replimune
Replimune
Forward Guidance
Based on the current operating plan, the Company believes that existing cash, cash equivalents and short-term investments, as of June 30, 2023, will enable the Company to fund operations into the second half of calendar year 2025.